Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

VIGIV

PreclinicalBiologic

Emergent BioSolutions

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Clinical

Trials by Indication[1]

Complication1 trial

VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection

Enrolling by invitation· Emergent BioSolutions logo

Emergent BioSolutions··NCT01374984·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VIGIV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VIGIV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VIGIV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Emergent BioSolutions company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Emergent BioSolutions

Related News